目的 探讨鼻渊通窍颗粒联合糠酸莫米松鼻喷雾剂治疗儿童过敏性鼻炎的临床疗效。方法 选取2017年8月—2018年10月在广东省妇幼保健院就诊的110例过敏性鼻炎患儿作为研究对象，按照随机数字表法将全部患者分为对照组和治疗组，每组各55例。对照组睡前鼻吸入糠酸莫米松鼻喷雾剂，2揿/鼻孔，1次/d。治疗组在对照组治疗的基础上温水口服鼻渊通窍颗粒，15 g/次，3次/d。两组患者均连续治疗8周。观察两组的临床疗效，比较两组的临床症状体征、血清因子指标。结果 治疗后，对照组和治疗组的总有效率分别为78.18%、92.73%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组的喷嚏、鼻塞、流涕、鼻痒、体征评分均明显降低，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗后，治疗组的喷嚏、鼻塞、流涕、鼻痒、体征评分均低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组的嗜酸粒细胞阳离子蛋白（ECP）、免疫球蛋白E（IgE）、血清细胞间黏附分子-1（ICAM-1）水平均显著降低，同组治疗前后差异具有统计学意义（P<0.05）；且治疗后，治疗组的ECP、IgE、ICAM-1水平均低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 鼻渊通窍颗粒联合糠酸莫米松鼻喷雾剂治疗儿童过敏性鼻炎具有较好的临床疗效，可改善临床症状体征，降低ECP、IgE、ICAM-1水平，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Biyuan Tongqiao Granules combined with Mometasone Furfurate Nasal Spray in treatment of allergic rhinitis in children. Methods Children (110 cases) with allergic rhinitis in Guangdong Maternal and Child Health Hospital from August 2017 to October 2018 were randomly divided into control and treatment groups, and each group had 55 cases. Patients in the control group were nasal inhalation administered with Mometasone Furoate Nasal Spray before bedtime, 2 presses/nostril, once daily. Patients in the treatment group were po administered with Biyuan Tongqiao Granules on the basis of the control group, 15 g/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and clinical symptoms and signs, and serum factor indexes in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 78.18% and 92.73%, respectively, and there was difference between two groups (P<0.05). After treatment, the scores of sneezing, nasal obstruction, runny nose, itching, and signs in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of ECP, IgE, and ICAM-1 in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Biyuan Tongqiao Granules combined with Mometasone Furfurate Nasal Spray has clinical curative effect in treatment of allergic rhinitis in children, can improve clinical symptoms and signs, and reduce the levels of ECP, IgE and ICAM-1, which has a certain clinical application value.